The Expanding Role for PARP Inhibition in Ovarian Cancer
WebcastFaculty
OVERVIEW
The Expanding Role for PARP Inhibition in Ovarian Cancer is organized by prIME oncology Oncology and will be held during Feb 15, 2017 - Feb 15, 2018.
The target audience for this medical event is intended for gynecologists, oncologists, radiation therapists, surgeons, pathologists, and other practitioners, including allied health professionals, involved in the diagnosis and management of gynecologic malignancies. This CME Conference has been approved for a maximum of 1.5 AMA PRA Category 1 Credits.
Conference Objectives are :
After successful completion of this educational activity, participants should be able to:
• Describe the mechanism of action of PARP inhibitors and identify predictive biomarkers of sensitivity beyond BRCA mutations
• Evaluate emerging data and ongoing clinical trials of maintenance therapy with PARP inhibitors in ovarian cancer and decide when to integrate the use of PARP inhibition into clinical practice
Additional details will be posted as soon as they are available.
The target audience for this medical event is intended for gynecologists, oncologists, radiation therapists, surgeons, pathologists, and other practitioners, including allied health professionals, involved in the diagnosis and management of gynecologic malignancies. This CME Conference has been approved for a maximum of 1.5 AMA PRA Category 1 Credits.
Conference Objectives are :
After successful completion of this educational activity, participants should be able to:
• Describe the mechanism of action of PARP inhibitors and identify predictive biomarkers of sensitivity beyond BRCA mutations
• Evaluate emerging data and ongoing clinical trials of maintenance therapy with PARP inhibitors in ovarian cancer and decide when to integrate the use of PARP inhibition into clinical practice
Additional details will be posted as soon as they are available.
SPECIALITIES
Oncology
Quick Links